Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy
Author:
Funder
Fulbright scholar research
L'Oreal UNESCO for Women in Science Levant and Egypt award
Al Jalila Foundation, United Arab Emirates
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference101 articles.
1. Tackling Cancer resistance by immunotherapy: updated clinical impact and safety of PD-1/PD-L1 inhibitors;Abdin;Cancers (Basel),2018
2. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016;Adusumilli;J. Immunother. Cancer,2017
3. INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors;Angevin;J. Clin. Oncol.,2017
4. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells;Arvey;Nat. Immunol.,2014
5. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat. Rev. Drug Discov.,2015
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds;Journal of Controlled Release;2024-09
2. LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer;Cell Biology and Toxicology;2024-01-25
3. Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach;Biomedicines;2024-01-18
4. Unveiling the Research Landscape and Emerging Trends in Cell Cycle for Cancer Immunotherapy: A Bibliometric Analysis (1990-2022);Medical Science Monitor;2023-10-11
5. High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome;Journal of Oncology;2023-02-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3